IL281277B2 - Preparations and methods for treating viral infections - Google Patents

Preparations and methods for treating viral infections

Info

Publication number
IL281277B2
IL281277B2 IL281277A IL28127721A IL281277B2 IL 281277 B2 IL281277 B2 IL 281277B2 IL 281277 A IL281277 A IL 281277A IL 28127721 A IL28127721 A IL 28127721A IL 281277 B2 IL281277 B2 IL 281277B2
Authority
IL
Israel
Prior art keywords
seq
sulfur atom
sulfur
another
cys10
Prior art date
Application number
IL281277A
Other languages
English (en)
Hebrew (he)
Other versions
IL281277A (en
IL281277B1 (en
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of IL281277A publication Critical patent/IL281277A/en
Publication of IL281277B1 publication Critical patent/IL281277B1/en
Publication of IL281277B2 publication Critical patent/IL281277B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL281277A 2018-09-06 2019-09-06 Preparations and methods for treating viral infections IL281277B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862727821P 2018-09-06 2018-09-06
US201862746865P 2018-10-17 2018-10-17
US201862782119P 2018-12-19 2018-12-19
US201962788386P 2019-01-04 2019-01-04
US201962813463P 2019-03-04 2019-03-04
US201962815235P 2019-03-07 2019-03-07
US201962832992P 2019-04-12 2019-04-12
US201962840899P 2019-04-30 2019-04-30
US201962852075P 2019-05-23 2019-05-23
US201962859983P 2019-06-11 2019-06-11
US201962873678P 2019-07-12 2019-07-12
US201962890475P 2019-08-22 2019-08-22
PCT/US2019/050018 WO2020051498A1 (en) 2018-09-06 2019-09-06 Compositions and methods for the treatment of viral infections

Publications (3)

Publication Number Publication Date
IL281277A IL281277A (en) 2021-04-29
IL281277B1 IL281277B1 (en) 2024-11-01
IL281277B2 true IL281277B2 (en) 2025-03-01

Family

ID=69722788

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281277A IL281277B2 (en) 2018-09-06 2019-09-06 Preparations and methods for treating viral infections

Country Status (18)

Country Link
US (3) US20210228727A1 (https=)
EP (1) EP3846846A4 (https=)
JP (2) JP7520816B2 (https=)
KR (1) KR20210079278A (https=)
CN (2) CN113194983B (https=)
AU (3) AU2019336230B2 (https=)
BR (1) BR112021004266A2 (https=)
CA (1) CA3111803A1 (https=)
CR (1) CR20210166A (https=)
EC (1) ECSP21023859A (https=)
IL (1) IL281277B2 (https=)
MA (1) MA53558A (https=)
MX (1) MX2021002569A (https=)
PH (1) PH12021550822A1 (https=)
SG (1) SG11202103313RA (https=)
TW (1) TWI840407B (https=)
WO (1) WO2020051498A1 (https=)
ZA (1) ZA202102158B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210079278A (ko) 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
TWI861205B (zh) * 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
US11253534B2 (en) 2020-03-23 2022-02-22 Sabine Hazan Method of preventing COVID-19 infection
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US11278520B2 (en) 2020-03-31 2022-03-22 Sabine Hazan Method of preventing COVID-19 infection
AU2021241498B2 (en) * 2020-03-23 2024-08-01 Sabine HAZAN Methods of preventing and treating COVID-19 infection
CN113801138B (zh) * 2020-06-12 2024-11-29 博瑞生物医药（苏州）股份有限公司 一种一锅法制备辛酸拉尼米韦中间体的方法
EP4192510A1 (en) 2020-08-06 2023-06-14 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
US20230364251A1 (en) 2020-08-06 2023-11-16 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
WO2022133281A1 (en) * 2020-12-17 2022-06-23 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
US20240285786A1 (en) * 2021-03-11 2024-08-29 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy
WO2023125806A1 (zh) * 2021-12-30 2023-07-06 苏州爱科百发生物医药技术有限公司 用于预防和治疗病毒感染的偶联物及其用途
JP2026508522A (ja) * 2023-03-01 2026-03-11 シダラ セラピューティクス インコーポレーテッド インフルエンザ感染を処置するための方法
WO2025002421A1 (zh) * 2023-06-29 2025-01-02 上海爱科百发生物医药技术股份有限公司 用于预防和治疗病毒感染的偶联物及其用途
WO2025119337A1 (zh) * 2023-12-08 2025-06-12 苏州拓界医药有限公司 一种抗病毒偶联物
WO2025157263A1 (zh) * 2024-01-26 2025-07-31 浙江养生堂天然药物研究所有限公司 偶联物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040136A1 (en) * 2001-11-09 2003-05-15 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335368A (en) 1996-11-14 2001-08-31 Biota Scient Management Macromolecular compound with one or more neuraminidase binders, binds to the active site of influenza virus neuraminidase
US6495580B1 (en) 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AUPP913999A0 (en) 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
SG122814A1 (en) 1999-06-28 2006-06-29 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors
CA2495266A1 (en) 2002-08-09 2004-02-19 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2006279304A1 (en) 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
CN103068378B (zh) * 2010-05-10 2016-07-06 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
MA34392B1 (fr) 2010-06-24 2013-07-03 Gilead Sciences Inc Pyrimidines en tant qu'agents antiviraux
RS55609B1 (sr) * 2011-04-13 2017-06-30 Bristol Myers Squibb Co Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US9834597B2 (en) 2012-09-21 2017-12-05 The Regents Of The University Of California Modified FC polypeptides, FC conjugates, and methods of use thereof
BR112015008325B1 (pt) 2012-10-16 2022-01-25 Janssen Sciences Ireland Uc Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
JP6211195B2 (ja) 2013-08-12 2017-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 呼吸器合胞体ウイルス感染症の処置および予防のための新規アザ−オキソ−インドール
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
WO2017046625A1 (en) * 2015-06-25 2017-03-23 Cube Biotech Gmbh New chelators for affinity purification of recombinant proteins
WO2018006063A1 (en) 2016-07-01 2018-01-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
US20230190950A1 (en) * 2017-01-06 2023-06-22 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
KR20210079278A (ko) * 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
EP3982994A4 (en) 2019-06-13 2023-10-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of respiratory syncytial virus
AU2020291469A1 (en) 2019-06-13 2022-02-10 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
US20240174730A1 (en) 2021-02-25 2024-05-30 Cidara Therapeutics, Inc. Variant fc domains and uses thereof
US20240285786A1 (en) 2021-03-11 2024-08-29 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040136A1 (en) * 2001-11-09 2003-05-15 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FU LIFENG ET AL:, STRUCTURE-BASED TETRAVALENT ZANAMIVIR WITH POTENTINHIBITORY ACTIVITY AGAINST DRUG-RESISTANT INFLUENZA VIRUSES, 14 July 2016 (2016-07-14) *
JENNIFER L. MCKIMM-BRESCHKIN ET AL:, TETHERED NEURAMINIDASEINHIBITORS THAT BIND AN INFLUENZA VIRUS: A FIRST STEP TOWARDS A DIAGNOSTICMETHOD FOR INFLUENZA, 14 July 2003 (2003-07-14) *
KEITH G. WATSON ET AL:, HIGHLY POTENT AND LONG-ACTING TRIMERIC ANDTETRAMERIC INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE, 6 March 2004 (2004-03-06) *
MACDONALD SIMON J. F. ET AL:, POTENT AND LONG-ACTING DIMERIC INHIBITORS OFINFLUENZA VIRUS NEURAMINIDASE ARE EFFECTIVE AT A ONCE-WEEKLY DOSINGREGIMEN, 12 December 2004 (2004-12-12) *
SIMON J. F. MACDONALD ET AL:, DIMERIC ZANAMIVIR CONJUGATES WITH VARIOUSLINKING GROUPS ARE POTENT, LONG-LASTING INHIBITORS OF INFLUENZA NEURAMINIDASEINCLUDING H5N1 AVIAN INFLUENZA, 8 April 2005 (2005-04-08) *
TENG-FEI ZHAO ET AL:, MULTIVALENT ZANAMIVIR-BOVINE SERUM ALBUMIN CONJUGATEAS A POTENT INFLUENZA NEURAMINIDASE INHIBITOR, 13 June 2017 (2017-06-13) *
WEN-HSIEN WEN ET AL:, SYNERGISTIC EFFECT OF ZANAMIVIR-PORPHYRIN CONJUGATESON INHIBITION OF NEURAMINIDASE AND INACTIVATION OF INFLUENZA VIRUS, 13 August 2009 (2009-08-13) *
WOLD ERIK D. ET AL:, FE-SMALL MOLECULE ANTIBODY MIMETICS, 13 November 2015 (2015-11-13) *

Also Published As

Publication number Publication date
MA53558A (fr) 2021-09-15
CN113194983A (zh) 2021-07-30
US12569565B2 (en) 2026-03-10
US20220257787A1 (en) 2022-08-18
CA3111803A1 (en) 2020-03-12
US20210228727A1 (en) 2021-07-29
CN121338028A (zh) 2026-01-16
BR112021004266A2 (pt) 2021-08-03
US20240156975A1 (en) 2024-05-16
AU2025271348A1 (en) 2025-12-18
AU2023278077A1 (en) 2024-01-18
JP7520816B2 (ja) 2024-07-23
MX2021002569A (es) 2021-06-08
CR20210166A (es) 2021-07-27
SG11202103313RA (en) 2021-04-29
ZA202102158B (en) 2024-06-26
KR20210079278A (ko) 2021-06-29
AU2019336230B2 (en) 2023-09-07
PH12021550822A1 (en) 2021-10-04
JP2024138422A (ja) 2024-10-08
IL281277A (en) 2021-04-29
JP2021536483A (ja) 2021-12-27
IL281277B1 (en) 2024-11-01
AU2023278077B2 (en) 2025-10-30
WO2020051498A1 (en) 2020-03-12
TW202104176A (zh) 2021-02-01
EP3846846A1 (en) 2021-07-14
AU2019336230A1 (en) 2021-04-15
TWI840407B (zh) 2024-05-01
EP3846846A4 (en) 2022-08-03
ECSP21023859A (es) 2021-06-30
CN113194983B (zh) 2025-11-18
US11833213B2 (en) 2023-12-05

Similar Documents

Publication Publication Date Title
IL281277B2 (en) Preparations and methods for treating viral infections
JP5788178B2 (ja) ウィルス感染症の治療のための組成物及び方法
CA2885169C (en) Diagnosis, prevention and treatment of diseases of the joint
DK2806896T3 (en) Chitosan covalently bound to small molecule integrin antagonist for targeted delivery
Maleki et al. Recent patents and FDA-approved drugs based on antiviral peptides and other peptide-related antivirals
Higgins et al. C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain–side chain crosslinking
Shah et al. Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19
KR20050120663A (ko) 장기간 작용하는 생물학적 활동 컨쥬게이트들
Jackman Antiviral peptide engineering for targeting membrane-enveloped viruses: Recent progress and future directions
Redman et al. Pharmacokinetic and chemical synthesis optimization of a potent D-peptide HIV entry inhibitor suitable for extended-release delivery
ATE482978T1 (de) Mimetische cd4-peptide und ihre verwendungen
Clayton et al. Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds
JPWO2020128527A5 (https=)
JPWO2020148526A5 (https=)
JPWO2020148525A5 (https=)
JPWO2020148528A5 (https=)
JPWO2021046549A5 (https=)
KR20060041163A (ko) 코로나바이러스에 의한 감염을 치료, 조절 및 예방하기위한 항바이러스 제제들
JPWO2020148527A5 (https=)
Wang et al. Peptide-based dual HIV and coronavirus entry inhibitors
CN109069577B (zh) Hiv进入的d-肽抑制剂以及使用方法
KR20200012894A (ko) 펩타이드 및 항바이러스제로서의 이의 용도
Kobayakawa et al. Bivalent HIV-1 fusion inhibitors based on peptidomimetics
JP2012530069A (ja) プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
Jiang et al. New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle